Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CGON reporting person James Mulay filed to potentially sell common stock through Morgan Stanley Smith Barney, indicating up to 20,237 shares with an aggregate value of $1,483,776.84 as of 07/10/2026. The shares relate to an exercise of stock options for cash and are listed on NASDAQ.
CGON Rule 144 notice reports an intended resale of 3,928 shares via exercise-related sale on 07/01/2026. The notice lists the broker Morgan Stanley Smith Barney LLC and indicates cash as the consideration method. Prior 10b5-1 dispositions by James Mulay are shown: 1,964 shares on 06/15/2026 for $118,075.68 and 15,600 shares on 04/17/2026 for $1,139,024.64.
CG Oncology, Inc. reported an open-market purchase of its Common Stock by Seven Fleet Partners LP, an entity associated with director Brian Guan-Chyun Liu. Seven Fleet Partners LP bought 371,085 shares at $66.87 per share on June 25, 2026, bringing its indirectly reported holdings to 1,886,236 shares.
Liu is the managing member of Seven Fleet Advisors, LLC, the investment manager of Seven Fleet Partners LP, and may be deemed to beneficially own these shares. He disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.
CG Oncology director Leonard E. Post reported coordinated stock transactions. On June 24, 2026, he sold 5,000 shares of Common Stock in an open-market transaction at $70.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2026.
On the same date, he exercised a director stock option to acquire 5,000 common shares at an exercise price of $0.60 per share. After these moves, he directly owned 5,000 common shares and held 106,077 director stock options expiring on July 8, 2028, indicating an exercise-and-sell pattern with a substantial remaining option position.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the sale of 5,000 shares of Common Stock. The filing lists an Exercise of Stock Options on 06/24/2026 for 5,000 shares to be settled for cash. The filing also discloses recent 10b5-1 executions by Leonard Post: 5,000 shares sold on 06/22/2026 for $325,000 and 1,000 shares sold on 06/04/2026 for $54,500.
CG Oncology director Leonard E. Post reported an option exercise and share sale. On June 22, 2026, he exercised options to acquire 5,000 shares of common stock at $0.60 per share and sold 5,000 shares at $65.00 in an open-market transaction. The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he reported no directly held common shares but retained 111,077 director stock options with a $0.60 exercise price expiring on July 8, 2028.
CGON filing a Rule 144 notice reporting the proposed sale of 6,000 common shares by an affiliated account on 06/22/2026. The filing also records a 10b5-1 sale of 1,000 common shares on 06/04/2026 for $54,500.00. The transaction method for the 6,000 shares is listed as exercise of stock options with cash used for the exercise.
CG Oncology, Inc. director James Mulay reported an exercise-and-sell transaction in company stock. He exercised options for a total of 1,964 shares of Common Stock at strike prices of $12.59 and $3.72 per share, then sold 1,964 shares in open-market trades at $60.12 per share.
The options exercised were Director Stock Options with expiration dates in 2033. A footnote states the sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2026, indicating these dispositions were scheduled in advance rather than timed discretionarily.
CG Oncology, Inc. reported the results of its 2026 annual stockholder meeting. As of the April 7, 2026 record date, 88,009,980 shares of common stock were outstanding and entitled to vote. Stockholders elected Class II directors Christina Rossi and Victor Tong, Jr. to terms running until the 2029 annual meeting.
Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In advisory votes, stockholders approved the compensation of named executive officers and expressed a preference for holding future advisory votes on executive pay every year, and the company will follow an annual frequency.
CG Oncology director Brian Guan-Chyun Liu received a grant of stock options for 9,354 shares of common stock. These Director Stock Options give him the right to buy shares at an exercise price of $56.09 per share and expire on June 3, 2036.
The options vest over time: 1/12 of the total vests monthly after the June 4, 2026 grant date, as long as he continues serving the company. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested portion will vest on that meeting date.